Cargando…

Combining radiotherapy with immunotherapy: the past, the present and the future

The advent of immunotherapy is currently revolutionizing the field of oncology, where different drugs are used to stimulate different steps in a failing cancer immune response chain. This review gives a basic overview of the immune response against cancer, as well as the historical and current evide...

Descripción completa

Detalles Bibliográficos
Autores principales:	Van Limbergen, Evert J, De Ruysscher, Dirk K, Olivo Pimentel, Veronica, Marcus, Damiënne, Berbee, Maaike, Hoeben, Ann, Rekers, Nicolle, Theys, Jan, Yaromina, Ala, Dubois, Ludwig J, Lambin, Philippe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The British Institute of Radiology. 2017
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5603954/ https://www.ncbi.nlm.nih.gov/pubmed/28541096 http://dx.doi.org/10.1259/bjr.20170157

Ejemplares similares

The immunocytokine L19-IL2: An interplay between radiotherapy and long-lasting systemic anti-tumour immune responses
por: Rekers, Nicolle H., et al.
Publicado: (2018)

Charged Particle and Conventional Radiotherapy: Current Implications as Partner for Immunotherapy
por: Marcus, Damiënne, et al.
Publicado: (2021)

Human fibronectin extra domain B as a biomarker for targeted therapy in cancer
por: Lieverse, Relinde I. Y., et al.
Publicado: (2020)

Releasing the brakes of tumor immunity with anti-PD-L1 and pushing its accelerator with L19–IL2 cures poorly immunogenic tumors when combined with radiotherapy
por: Olivo Pimentel, Veronica, et al.
Publicado: (2021)

Immunotherapy as sensitizer for local radiotherapy
por: Vanneste, Ben G.L., et al.
Publicado: (2020)

Long-lasting antitumor effects provided by radiotherapy combined with the immunocytokine L19-IL2
por: Rekers, Nicolle H, et al.
Publicado: (2015)

Evofosfamide sensitizes esophageal carcinomas to radiation without increasing normal tissue toxicity
por: Spiegelberg, Linda, et al.
Publicado: (2019)

An overview of the published and running randomized phase 3 clinical results of radiotherapy in combination with immunotherapy
por: Vanneste, Ben G. L., et al.
Publicado: (2021)

Hypoxia-activated prodrugs and (lack of) clinical progress: The need for hypoxia-based biomarker patient selection in phase III clinical trials
por: Spiegelberg, Linda, et al.
Publicado: (2019)

Hypoxia PET Imaging with [18F]-HX4—A Promising Next-Generation Tracer
por: Sanduleanu, Sebastian, et al.
Publicado: (2020)

Combining hypoxia-activated prodrugs and radiotherapy in silico: Impact of treatment scheduling and the intra-tumoural oxygen landscape
por: Hamis, Sara, et al.
Publicado: (2020)

Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial
por: Lieverse, Relinde I. Y., et al.
Publicado: (2020)

Radiation for Oligometastatic Lung Cancer in the Era of Immunotherapy: What Do We (Need to) Know?
por: Peeters, Stephanie T. H., et al.
Publicado: (2021)

Homologous Recombination Deficiency Scar: Mutations and Beyond—Implications for Precision Oncology
por: van der Wiel, Alexander M. A., et al.
Publicado: (2022)

Efficient Secretion of Murine IL-2 From an Attenuated Strain of Clostridium sporogenes, a Novel Delivery Vehicle for Cancer Immunotherapy
por: Kubiak, Aleksandra M., et al.
Publicado: (2021)

Prognostic Significance of Carbonic Anhydrase IX Expression in Cancer Patients: A Meta-Analysis
por: van Kuijk, Simon J. A., et al.
Publicado: (2016)

Prediction models for brachytherapy-induced rectal toxicity in patients with locally advanced pelvic cancers: a systematic review
por: Tohidinezhad, Fariba, et al.
Publicado: (2022)

Polyphenols as Potential Protectors against Radiation-Induced Adverse Effects in Patients with Thoracic Cancer
por: Prades-Sagarra, Èlia, et al.
Publicado: (2023)

Advancing Clostridia to Clinical Trial: Past Lessons and Recent Progress
por: Mowday, Alexandra M., et al.
Publicado: (2016)

Nitroglycerin as a radiosensitizer in non-small cell lung cancer: Results of a prospective imaging-based phase II trial
por: Reymen, Bart J.T., et al.
Publicado: (2019)

Synergistic Effects of NOTCH/γ-Secretase Inhibition and Standard of Care Treatment Modalities in Non-small Cell Lung Cancer Cells
por: Sosa Iglesias, Venus, et al.
Publicado: (2018)

BioXmark® liquid fiducials to enable radiotherapy tumor boosting in rectal cancer, a feasibility trial
por: Opbroek, Thirza J.S., et al.
Publicado: (2022)

In vivo optical imaging of MMP2 immuno protein antibody: tumor uptake is associated with MMP2 activity
por: Panth, Kranthi Marella, et al.
Publicado: (2016)

HIF-1α and HIF-2α Differently Regulate the Radiation Sensitivity of NSCLC Cells
por: Moreno Roig, Eloy, et al.
Publicado: (2019)

A biodegradable rectal balloon implant to protect the rectum during prostate cancer radiotherapy for a patient with active Crohn’s disease
por: Vanneste, Ben G.L., et al.
Publicado: (2018)

Use of a Luciferase-Expressing Orthotopic Rat Brain Tumor Model to Optimize a Targeted Irradiation Strategy for Efficacy Testing with Temozolomide
por: Mowday, Alexandra M., et al.
Publicado: (2020)

Prognostic Role of Hypoxia-Inducible Factor-2α Tumor Cell Expression in Cancer Patients: A Meta-Analysis
por: Moreno Roig, Eloy, et al.
Publicado: (2018)

Chloroquine combined with concurrent radiotherapy and temozolomide for newly diagnosed glioblastoma: a phase IB trial
por: Compter, Inge, et al.
Publicado: (2020)

A scoping review of small animal image-guided radiotherapy research: Advances, impact and future opportunities in translational radiobiology
por: Brown, Kathryn H., et al.
Publicado: (2022)

Patient-Derived Cancer Organoids as Predictors of Treatment Response
por: Verduin, Maikel, et al.
Publicado: (2021)

GEC ESTRO ACROP consensus recommendations for contact brachytherapy for rectal cancer
por: Stewart, Alexandra J., et al.
Publicado: (2021)

The posterior cerebellum, a new organ at risk?
por: Eekers, Daniëlle B.P., et al.
Publicado: (2017)

Cancer immunotherapy: from the lab to clinical applications—Potential impact on cancer centres’ organisation
por: Cairns, Linda, et al.
Publicado: (2016)

Novel fluorinated carbonic anhydrase IX inhibitors reduce hypoxia-induced acidification and clonogenic survival of cancer cells
por: Kazokaitė, Justina, et al.
Publicado: (2018)

What is the degree of innovation routinely implemented in Dutch radiotherapy centres? A multicentre cross-sectional study
por: Jacobs, Maria, et al.
Publicado: (2016)

What is the impact of innovation on output in healthcare with a special focus on treatment innovations in radiotherapy? A literature review
por: Jacobs, Maria, et al.
Publicado: (2017)

The Sulfamate Small Molecule CAIX Inhibitor S4 Modulates Doxorubicin Efficacy
por: van Kuijk, Simon J. A., et al.
Publicado: (2016)

Selectively Targeting Tumor Hypoxia With the Hypoxia-Activated Prodrug CP-506
por: van der Wiel, Alexander M.A., et al.
Publicado: (2021)

Lymph node response to chemoradiotherapy in oesophageal cancer patients: relationship with radiotherapy fields
por: Koemans, Willem J., et al.
Publicado: (2020)

Predicting the Tumour Response to Radiation by Modelling the Five Rs of Radiotherapy Using PET Images
por: Hami, Rihab, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_0r228he1vuvnlfkjf1u6erq2e4